Antibodies and antigen-binding fragments thereof that bind type II transmembrane serine protease 6 (TMPRSS6) on the surface of a cell and increase hepcidin expression, and methods for treating disorders of iron metabolism using anti TMPRSS6 antibodies and fragments, are provided.

This disclosure relates to methods of treating cancer using a combination of an anti-CD40 antibody such as SEA-CD40, and an anti-PD-1 antibody such as pembrolizumab. The treatment can further include a chemotherapy.

Disclosed is an anti-CTLA-4 monoclonal antibody and a preparation and use thereof. The anti-CTLA-4 antibody has the advantages of lower toxicity and better activity; in addition, the anti-CTLA-4 antibody also has a low content of high mannose glycoforms and/or a low content of sialylated glycoforms, which helps to prolong the half-life of the antibody and/or reduce immunogenicity. In addition, disclosed is a formulation with the antibody which has good stability.

The present invention provides for recombinant Endo-D and selected mutants that exhibit reduced hydrolysis activity and increased transglycosylation activity for the synthesis of glycoproteins wherein a desired sugar chain is added to a core fucosylated or nonfucosylated GlcNAc-protein acceptor by transglycosylation. Such recombinant Endo-D and selected mutants are useful for efficient glycosylation remodeling of IgG1-Fc domain.

Humanized antibodies and antibody fragments that bind to αvβ5 are disclosed. Also disclosed are methods of using the disclosed antibodies and antibody fragments to treat or prevent αvβ5-mediated diseases.

The present invention provides a method for manipulating the fucosylated glycan content on a recombinant protein.

Provided are salt-free antibody and other protein formulations that are substantially isosmotic and of low viscosity. Also provided are methods for the treatment of diseases using the disclosed formulations.

The present invention relates to methods of modulating the mannose content of recombinant proteins.

Genetically engineered antibodies containing non-native N-glycosylated sites, preparation of the antibodies in yeast and fungi, site-specific conjugation of drugs to these antibodies, and methods of treatment utilizing these antibodies are described herein.

The disclosure relates to means and methods in the treatment of cancer. The disclosure in particular relates to a method of treating a cancer in an individual with an antibody that binds LGR5 and EGFR. The invention further relates to the combination for use in such methods and to the combination for use in the manufacture of a medicament for the treatment of gastrointestinal cancer. Such antibodies are particularly useful in the treatment of gastric, esophageal, or gastro-esophageal-junction cancer.